Medicare for All Act
- Sponsor
- Rep. Jayapal, Pramila [D-WA-7]
- Committees
- Judiciary Committee (primary)
- Last action
- Apr 29, 2025
Bottom line
The 'Medicare for All Act' proposes a complete overhaul of the U.S. healthcare system, transitioning to a single-payer model with universal coverage, comprehensive benefits, and the elimination of private insurance for covered services.
What it actually does
This bill establishes a national health insurance program, termed 'Medicare for All,' providing universal coverage for all U.S. residents with comprehensive benefits and no cost-sharing. It phases out existing federal health programs like Medicare, Medicaid, and TRICARE's purchased care component, and prohibits private health insurance from duplicating covered benefits. The program would be funded through a Universal Medicare Trust Fund, with a transition period of two years.
Proponents argue
Supporters argue that this bill would guarantee healthcare as a human right, ensuring every person in the United States has access to comprehensive medical care without financial barriers like premiums, deductibles, or copayments. They contend it would significantly reduce overall healthcare costs through global budgeting, negotiated drug prices, and administrative simplification, while improving health outcomes and addressing disparities by focusing on prevention and primary care.
Opponents contend
Critics argue that the bill represents a government takeover of healthcare, eliminating patient choice and private insurance options. They contend that the massive cost of such a program would necessitate substantial tax increases, potentially leading to economic disruption and long wait times for care. Opponents also raise concerns about the federal government's capacity to manage such a vast system and the potential for reduced innovation in the pharmaceutical and medical device industries.
The bill is 49 pages long and highly complex, requiring significant time for a thorough review. Given its transformative nature, the time needed for public and expert evaluation is substantial.
Title I, Sec. 101-107
Establishment of Universal Coverage and Program Framework
This title establishes the 'Medicare for All Program' as a national health insurance program, guaranteeing universal coverage for all U.S. residents. It ensures freedom of choice for individuals to obtain services from any qualified provider and prohibits discrimination in the provision of benefits. Crucially, it makes it unlawful for private health insurers or employers to offer coverage that duplicates benefits provided under this Act, effectively phasing out most private health insurance for covered services after a two-year transition.
Supporters argue
Supporters argue that universal coverage ensures healthcare access for everyone, eliminating financial barriers and the risk of medical bankruptcy. The prohibition on duplicative private insurance is seen as essential to create a true single-payer system, streamline administration, and prevent a two-tiered healthcare system.
Critics contend
Critics contend that eliminating private insurance would remove patient choice, disrupt existing employer-sponsored plans, and lead to job losses in the insurance industry. They argue that a government-run system could lead to rationing of care and longer wait times.
Tradeoffs
The provision balances the goal of universal, equitable access against concerns about individual choice, market disruption, and the role of private enterprise in healthcare.
Title II, Sec. 201-204
Comprehensive Benefits and No Cost-Sharing
This title outlines a comprehensive benefits package, including hospital services, ambulatory care, primary and preventive services, prescription drugs, mental health and substance use treatment, laboratory and diagnostic services, reproductive care (including abortion and gender-affirming care), maternity and newborn care, oral health, audiology, vision, rehabilitative services, emergency services, and long-term care. It explicitly prohibits any cost-sharing (deductibles, copayments, coinsurance), balance billing, or prior authorization requirements for covered services. The Secretary is mandated to annually evaluate and recommend improvements to the benefits package.
Title III, Sec. 301-303
Provider Participation and Restrictions on Private Contracts
This title outlines the requirements for healthcare providers to participate in the Medicare for All program, including licensing, non-discrimination, and uniform reporting standards. It establishes a 'duty of provider ethics' prohibiting financial incentives based on patient utilization or financial outcomes, and bans board members/executives of institutional providers from having financial interests in entities contracting with the provider. Significantly, it prohibits participating providers from entering into private contracts with eligible individuals for covered services, effectively preventing a parallel private market for core medical care. Non-participating providers can enter private contracts for covered services, but must sign an affidavit foregoing Medicare for All payments for two years.
Title VI, Sec. 601, 611-617
National Health Budget, Provider Payments, and Drug Price Negotiation
This title establishes a national health budget, allocated annually by the Secretary into components like operating, capital, and special projects budgets, with regional allotments. Institutional providers (hospitals, skilled nursing facilities) will be paid through global budgets negotiated annually with regional directors, covering all operating expenses. Individual providers will be paid via a national fee-for-service schedule. The title explicitly prohibits payments for marketing, profit, incentive payments, and political contributions. It also establishes an Office of Health Equity and an Office of Primary Care. A key provision mandates the Secretary to negotiate prescription drug prices annually, with a 'competitive licensing authority' to allow generic manufacturing if negotiations fail, based on factors including R&D investment and comparative effectiveness.
Title VII, Sec. 701
Universal Medicare Trust Fund Establishment and Funding
This section establishes the Universal Medicare Trust Fund in the U.S. Treasury to finance the Medicare for All Program. It mandates appropriations into this fund from the net increase in revenues attributable to the elimination of duplicative employee benefits (under ERISA) and the sunset of State Exchanges. It also appropriates amounts equivalent to current federal spending on Medicare, Medicaid, FEHBP, TRICARE's purchased care, and other federal health programs, adjusted annually. Crucially, it states that existing restrictions on federal funds for reproductive health services shall not apply to monies in this Trust Fund.
Title VIII, Sec. 801-803
Conforming Amendments to ERISA and Workers' Compensation
This title amends the Employee Retirement Income Security Act of 1974 (ERISA) to prohibit employee benefit plans from providing benefits that duplicate those offered under the Medicare for All Act, reinforcing the elimination of private insurance for covered services. It also mandates that workers' compensation carriers reimburse the Medicare for All Program for the cost of services provided to injured workers, ensuring that the new program is not burdened by existing workers' compensation liabilities. Continuation coverage requirements under ERISA (like COBRA) would only apply to health plans offering non-duplicative benefits.
Title IX, Sec. 901-903
Sunset of Existing Federal Health Programs and State Exchanges
This title mandates the sunset of major existing federal health programs for individuals eligible for Medicare for All, including Medicare (Title XVIII), Medicaid (Title XIX), and the State Children's Health Insurance Program (SCHIP, Title XXI). It also terminates the Federal Employees Health Benefits Program (FEHBP) and the purchased care component of the TRICARE program (with an exception for TRICARE Overseas). The Federal and State Exchanges established under the Affordable Care Act are terminated, along with all federal pay-for-performance and value-based purchasing programs. Special provisions ensure continuity of care during the transition for inpatient and extended care services and maintain school-related health programs.
Title X, Sec. 1001-1012
Transition to Medicare for All and Transitional Buy-In Option
This title outlines a two-year transition period for the full implementation of Medicare for All. During the first year, individuals aged 18 and younger, or 55 and older, become eligible for Medicare for All benefits. It also establishes a 'Medicare Transition Buy-In' option, available through the Affordable Care Act Exchanges, allowing any U.S. resident to purchase coverage under the new Medicare for All benefit structure during the transition period. This buy-in provides comprehensive benefits with no cost-sharing and uses Medicare for All reimbursement rates. Tax credits and cost-sharing subsidies are made available for buy-in enrollees, including enhanced subsidies for those in non-Medicaid expansion states. The title also eliminates the 24-month waiting period for Medicare coverage for individuals with disabilities during this transition and ensures continuity of care for all persons, especially those with complex medical needs.
The Secretary may make other individuals eligible for benefits, but must ensure they do not travel to the U.S. solely for health care under the program.
Sec. 102(b), Title I
Why it matters:This is standard legislative practice to grant administrative flexibility while also addressing potential concerns about 'health tourism' that might arise with universal coverage.
Case for: Proponents would argue this provides necessary flexibility for the Secretary to cover specific populations (e.g., asylum seekers, temporary residents) while including a safeguard against potential abuse of the system.
Case against: Critics might argue that the 'sole purpose' clause is difficult to enforce and could lead to arbitrary denials of care or create administrative burdens for individuals seeking legitimate care.
Estimated impact: Potentially affects a small but significant population of non-resident individuals who might otherwise lack access to care, and introduces a new administrative determination for eligibility.
Prohibits board members, executives, or administrators of institutional providers from receiving compensation from, owning stock in, or serving on the board of any entity that contracts with or provides items/services (including drugs/devices) to that institutional provider.
Sec. 301(b)(1)(I) and (b)(2)(C), Title III
Why it matters:This is a strong anti-corruption and conflict-of-interest measure, which, while highly impactful, is placed within technical administrative requirements rather than a standalone 'ethics' title.
Case for: Proponents argue this is essential to eliminate conflicts of interest that can drive up costs and compromise patient care, ensuring that decisions are made in the best interest of the public, not for private financial gain.
Case against: Critics might argue that such strict prohibitions could make it difficult to recruit qualified individuals for leadership positions in healthcare institutions, particularly those with diverse business backgrounds or investments in the broader healthcare ecosystem.
Estimated impact: Significant restructuring of governance and financial relationships within institutional healthcare providers, potentially leading to a more transparent and patient-focused system.
Compensation costs for any employee, contractor, or subcontractor employee of an institutional provider receiving global budgets shall meet the compensation cap established in section 702 of the Bipartisan Budget Act of 2013 (41 U.S.C. 4304(a)(16)).
Sec. 611(b)(4), Title VI
Why it matters:This is a technical cross-reference to an existing federal compensation cap, which is a common legislative drafting technique. However, its application to all employees/contractors of institutional providers under M4A is a significant policy choice.
Case for: Proponents would argue this ensures responsible use of public funds, preventing excessive compensation within institutions funded by the national health budget and aligning with broader federal spending principles.
Case against: Critics might argue that applying a federal compensation cap to all employees and contractors of healthcare institutions could make it difficult to attract and retain top talent, particularly in specialized medical fields or competitive markets, potentially impacting quality of care.
Estimated impact: Potentially caps salaries for high-earning healthcare professionals and administrators within institutional settings, leading to a redistribution of compensation within the healthcare workforce.
Establishes a 'competitive licensing authority' for the Secretary: if drug price negotiations fail, the Secretary can authorize the use of any patent, clinical trial data, or other exclusivity for manufacturing the drug for the Medicare for All Program, with reasonable compensation to the original manufacturer.
Sec. 617(3), Title VI
Why it matters:This is a highly significant and controversial policy mechanism that could fundamentally alter the pharmaceutical market. Its placement within a payment section, rather than a standalone 'drug innovation' title, might obscure its profound implications.
Case for: Proponents argue this is a critical tool to ensure affordable access to essential medicines, especially when pharmaceutical companies refuse to negotiate reasonable prices. It acts as a backstop to price negotiation, prioritizing public health over corporate profits.
Case against: Critics, particularly the pharmaceutical industry, would argue this undermines intellectual property rights, disincentivizes research and development of new drugs, and could lead to a decline in pharmaceutical innovation, ultimately harming patients.
Estimated impact: Potentially massive impact on pharmaceutical company revenues, drug pricing, and the global pharmaceutical R&D landscape, leading to significantly lower drug costs for the program and patients.
Prohibits the use of any funds, facilities, property, equipment, or personnel made available by this Act for law enforcement or assistance in investigation/enforcement of criminal, civil, or administrative violations related to requirements that individuals register with the Federal Government based on religion, national origin, ethnicity, immigration status, or other protected category.
Sec. 1103, Title XI
Why it matters:This is a civil liberties and immigration-related policy rider attached to a healthcare bill. Its placement at the very end might be to avoid drawing immediate attention to a provision unrelated to the core healthcare policy.
Case for: Proponents argue this is a crucial protection to ensure that healthcare access is truly universal and non-discriminatory, preventing healthcare resources from being co-opted for unrelated law enforcement purposes that could deter vulnerable populations from seeking care.
Case against: Critics might argue that this provision could hinder legitimate law enforcement or national security efforts by restricting data sharing or resource use, potentially creating a 'sanctuary' within the healthcare system.
Estimated impact: Ensures that individuals, particularly immigrants and minority groups, can access healthcare without fear of their information being used for unrelated law enforcement or immigration purposes, potentially increasing utilization among these groups.